Page 54 - AN-1-3

Advanced Neurology The diagnosis and treatment of anti-LGI1 autoimmune encephalitis

encephalitis. Ann Clin Transl Neurol, 8: 763–773. https://doi.org/10.1212/WNL.0000000000007475

https://doi.org/10.1002/acn3.51313 77. Guo K, Liu X, Lin J, et al., 2022, Clinical characteristics,
long-term functional outcomes and relapse of anti-LGI1/
73. Ghimire P, Khanal UP, Gajurel BP, et al., 2020, Anti-LGI1,
anti-GABABR, and anti-CASPR2 encephalitides in Asia: Caspr2 encephalitis: A prospective cohort study in Western
A systematic review. Brain Behav, 10: e01793. China. Ther Adv Neurol Disord, 15.
https://doi.org/10.1177/17562864211073203
https://doi.org/10.1002/brb3.1793
78. Arino H, Armangue T, Petit-Pedrol M, et al., 2016, Anti-
74. Nepal G, Shing YK, Yadav JK, et al., 2020, Efficacy and safety
of rituximab in autoimmune encephalitis: A meta-analysis. LGI1-associated cognitive impairment: Presentation and
Acta Neurol Scand, 142: 449–459. long-term outcome. Neurology, 87: 759–765.
https://doi.org/10.1212/WNL.0000000000003009
https://doi.org/10.1111/ane.13291
79. Bien CG, Urbach H, Schramm J, et al., 2007, Limbic
75. Lee WJ, Lee ST, Moon J, et al., 2016, Tocilizumab in
autoimmune encephalitis refractory to rituximab: An encephalitis as a precipitating event in adult-onset temporal
institutional cohort study. Neurotherapeutics, 13: 824–832. lobe epilepsy. Neurology, 69: 1236–1244.
https://doi.org/10.1212/01.wnl.0000276946.08412.ef
https://doi.org/10.1007/s13311-016-0442-6
80. Bien CG, Vincent A, Barnett MH, et al., 2012,
76. De Bruijn MA, van Sonderen A, van Coevorden-Hameete MH,
et al., 2019, Evaluation of seizure treatment in anti-LGI1, Immunopathology of autoantibody-associated encephalitides:
anti-NMDAR, and anti-GABA(B)R encephalitis. Neurology, Clues for pathogenesis. Brain, 135(Pt 5): 1622–1638.
92: e2185–e2196. https://doi.org/10.1093/brain/aws082

Volume 1 Issue 3 (2022) 11 https://doi.org/10.36922/an.v1i3.237